Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 126 full-time employees. The company went IPO on 2021-03-26. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The firm is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
Follow-Up Questions
Edgewise Therapeutics Inc のCEOは誰ですか？
Dr. Kevin Koch は Edgewise Therapeutics Inc の President で、2017 から在籍しています。
